Introduction:
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-appreciated disease. The aim of this study was to evaluate the T-Amylo score, i.e., ATTR-CM related, in relation to all-cause and cardiovascular disease (CVD) morbidity and mortality, in the general population.

Material and methods:
The T-Amylo score (range 0-11) is based on clinical and echocardiographic features (age and gender, IVSd thickness >=16 mm, low QRS interval voltage, and carpal tunnel syndrome) that have been previously introduced in clinical practice.

Results:
During 2009, 1,420 middle aged and older inhabitants agreed to enroll into the Ikaria study (678 males aged 67(14) years, and 742 females aged 66(14) years); in 2013, the participants were re-evaluated. Survival analysis revealed that the T-Amylo prediction score was associated with all-cause mortality (Hazard Ratio 1.59, 95%CI 1.40 to 1.81), and the risk of combined CVD events (1.32, 95%CI 1.11 to 1.56), after various adjustments made. ROC analysis revealed that the AUC of T-Amylo score was 0.70, the accuracy was 81.52%, and the net-reclassification indices suggested better reclassification performance than its components. Stratifying by age group, the score predicts all-cause and CVD mortality and morbidity only among >65 years old individuals.

Conclusions:
The prognostic value for CVDs of the T-Amylo score observed here seems promising for its use in the general population, too.